----item----
version: 1
id: {23196F76-3164-4A6B-BCED-A71667B14424}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/12/02/Apotex 2nd biosimilar under FDA review seeks filgrastim OK
parent: {A4DA0C5F-4495-437C-8ACE-4424E2BEFF66}
name: Apotex 2nd biosimilar under FDA review seeks filgrastim OK
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 117c8d8b-14df-4658-8db3-a6edd4c377f0

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{F33C567E-43AA-4F5D-A484-E2C7F5C08D89}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 59

Apotex 2nd biosimilar under FDA review; seeks filgrastim OK
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 58

Apotex 2nd biosimilar under FDA review seeks filgrastim OK
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3022

<p>The FDA is reviewing a second biosimilar application from Canadian drug maker Apotex &ndash; this time a version of Amgen's Neupogen (filgrastim), which made about $1bn in sales last year.</p><p>Privately held Apotex, which has jointed developed the filgrastim biosimilar with Intas Pharmaceuticals, is seeking to market the product in the US under the brand name Grastofil. </p><p>The product, if approved, will be sold in the US by Apotex's subsidiary ApoBiologix. </p><p>Apotex already has a biosimilar application under the FDA's 351(k) abbreviated approval pathway before the agency &ndash; a version of Amgen's Neulasta (pegfilgrastim), a long-acting form of Neupogen, a human granulocyte colony-stimulating factor (scripintelligence.com, <a href="http://www.scripintelligence.com/policyregulation/Apotex-biosimilar-of-Amgens-Neulasta-under-FDA-review-355732" target="_new">18 December 2014</a>).</p><p>Novartis unit Sandoz currently is awaiting a decision from the FDA on its filgrastim biosimilar, which it plans to market in the US as Zarxio &ndash; a slightly different spelling than the moniker it goes under in Europe, Zarzio.</p><p>In January, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 14-0 the totality of evidence supported licensing of Zarxio for all of the five indications approved for Neupogen &ndash; the first time ever a panel of the agency's outside experts had met to examine a 351(k) biosimilar application (scripintelligence.com, <a href="http://www.scripintelligence.com/home/NovartisSandoz-biosimilar-1st-to-win-FDA-panel-backing-355993" target="_new">8 January 2015</a>, <a href="http://www.scripintelligence.com/home/comment/FDAs-1st-biosimilar-adcomm-a-lovefest-355994" target="_new">8 January 2015</a>).</p><p>The FDA's Arthritis Advisory Committee will meet on 17 March to discuss the 351(k) biosimilar application for Celltrion's infliximab product, known as CTP13, which is referenced from Johnson & Johnson's Remicade (scripintelligence.com, <a href="http://www.scripintelligence.com/home/Will-FDA-adcomm-be-lucky-for-Celltrion-infliximab-biosimilar-356630" target="_new">9 February 2015</a>).</p><p>Another firm seeking the FDA&rsquo;s nod in the US for a biosimilar is Hospira, which is seeking to market an epoetin alfa version of Amgen&rsquo;s Epogen and J&J&rsquo;s Procrit (scripintelligence.com, <a href="http://www.scripintelligence.com/policyregulation/Hospira-seeks-FDA-nod-for-EpogenProcrit-biosimilar-356100" target="_new">13 January 2015</a>).</p><p>"The benefits for patients, payers and providers from biosimilars will be significant," said Jeremy Desai, Apotex's president and CEO.</p><p>"We are very pleased to be at the forefront of companies who will introduce high quality biosimilar products into the US marketplace," he said. "Our entry into this new frontier of medicine in the United States is a watershed event in Apotex's 40 year history of providing quality, affordable medicines to patients in need around the globe."</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 195

<p>The FDA is reviewing a second biosimilar application from Canadian drug maker Apotex &ndash; this time a version of Amgen's Neupogen (filgrastim), which made about $1bn in sales last year.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 58

Apotex 2nd biosimilar under FDA review seeks filgrastim OK
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151202T150000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151202T150000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151202T150000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027853
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 59

Apotex 2nd biosimilar under FDA review; seeks filgrastim OK
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

headline news
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356719
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042256Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

117c8d8b-14df-4658-8db3-a6edd4c377f0
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042256Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
